1
|
Fauconnier MB, Burnier P, Jankowski C, Loustalot C, Coutant C, Vincent L. Comparison of postoperative complications following conventional latissimus dorsi flap versus muscle-sparing latissimus dorsi flap breast reconstruction. J Plast Reconstr Aesthet Surg 2022; 75:3653-3663. [DOI: 10.1016/j.bjps.2022.06.084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2022] [Revised: 05/31/2022] [Accepted: 06/21/2022] [Indexed: 11/30/2022]
|
2
|
Nambot S, Sawka C, Bertolone G, Cosset E, Goussot V, Derangère V, Boidot R, Baurand A, Robert M, Coutant C, Loustalot C, Thauvin-Robinet C, Ghiringhelli F, Lançon A, Populaire C, Damette A, Collonge-Rame MA, Meunier-Beillard N, Lejeune C, Albuisson J, Faivre L. Incidental findings in a series of 2500 gene panel tests for a genetic predisposition to cancer: Results and impact on patients. Eur J Med Genet 2021; 64:104196. [PMID: 33753322 DOI: 10.1016/j.ejmg.2021.104196] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2020] [Revised: 02/02/2021] [Accepted: 03/14/2021] [Indexed: 10/21/2022]
Abstract
With next generation sequencing, physicians are faced with more complex and uncertain data, particularly incidental findings (IF). Guidelines for the return of IF have been published by learned societies. However, little is known about how patients are affected by these results in a context of oncogenetic testing. Over 4 years, 2500 patients with an indication for genetic testing underwent a gene cancer panel. If an IF was detected, patients were contacted by a physician/genetic counsellor and invited to take part in a semi-structured interview to assess their understanding of the result, the change in medical care, the psychological impact, and the transmission of results to the family. Fourteen patients (0.56%) were delivered an IF in a cancer predisposition gene (RAD51C, PMS2, SDHC, RET, BRCA2, CHEK2, CDKN2A, CDH1, SUFU). Two patients did not collect the results and another two died before the return of results. Within the 10 patients recontacted, most of them reported surprise at the delivery of IF, but not anxiety. The majority felt they had chosen to obtain the result and enough information to understand it. They all initiated the recommended follow-up and did not regret the procedure. Information regarding the IF was transmitted to their offspring but siblings or second-degree relatives were not consistently informed. No major adverse psychological events were found in our experience. IF will be inherent to the development of sequencing, even for restricted gene panels, so it is important to increase our knowledge on the impact of such results in different contexts.
Collapse
Affiliation(s)
- S Nambot
- Centre de Génétique, FHU TRANSLAD, Institut GIMI, CHU Dijon, F-21000, Dijon, France; CGFL, Unité D'oncogénétique et Institut GIMI, F-21000, Dijon, France.
| | - C Sawka
- Centre de Génétique, FHU TRANSLAD, Institut GIMI, CHU Dijon, F-21000, Dijon, France; CGFL, Unité D'oncogénétique et Institut GIMI, F-21000, Dijon, France
| | - G Bertolone
- Centre de Génétique, FHU TRANSLAD, Institut GIMI, CHU Dijon, F-21000, Dijon, France; CGFL, Unité D'oncogénétique et Institut GIMI, F-21000, Dijon, France
| | - E Cosset
- CGFL, Unité D'oncogénétique et Institut GIMI, F-21000, Dijon, France
| | - V Goussot
- Platform of Transfer in Cancer Biology, Department of Biology and Pathology of Tumours, Centre Georges-François Leclerc, Unicancer, F-21000, Dijon, France
| | - V Derangère
- Platform of Transfer in Cancer Biology, Department of Biology and Pathology of Tumours, Centre Georges-François Leclerc, Unicancer, F-21000, Dijon, France
| | - R Boidot
- Platform of Transfer in Cancer Biology, Department of Biology and Pathology of Tumours, Centre Georges-François Leclerc, Unicancer, F-21000, Dijon, France; CNRS, 6302 Unit, Dijon, France
| | - A Baurand
- Centre de Génétique, FHU TRANSLAD, Institut GIMI, CHU Dijon, F-21000, Dijon, France; CGFL, Unité D'oncogénétique et Institut GIMI, F-21000, Dijon, France
| | - M Robert
- Centre de Génétique, FHU TRANSLAD, Institut GIMI, CHU Dijon, F-21000, Dijon, France
| | - C Coutant
- Département de Chirurgie, Centre Georges François Leclerc, F-21000, Dijon, France
| | - C Loustalot
- Département de Chirurgie, Centre Georges François Leclerc, F-21000, Dijon, France
| | - C Thauvin-Robinet
- Centre de Génétique, FHU TRANSLAD, Institut GIMI, CHU Dijon, F-21000, Dijon, France
| | - F Ghiringhelli
- Platform of Transfer in Cancer Biology, Department of Biology and Pathology of Tumours, Centre Georges-François Leclerc, Unicancer, F-21000, Dijon, France; Département D'oncologie Médicale, Centre Georges François Leclerc, Dijon, France; Centre de Recherche INSERM LNC-UMR123, Université de Bourgogne Franche-Comté, F-21000, Dijon, France
| | - A Lançon
- CGFL, Unité D'oncogénétique et Institut GIMI, F-21000, Dijon, France
| | - C Populaire
- Service Génétique et Biologie Du Développement-Histologie, CHU Hôpital Saint-Jacques, Besançon, France
| | - A Damette
- Service Génétique et Biologie Du Développement-Histologie, CHU Hôpital Saint-Jacques, Besançon, France
| | - M A Collonge-Rame
- Service Génétique et Biologie Du Développement-Histologie, CHU Hôpital Saint-Jacques, Besançon, France
| | - N Meunier-Beillard
- INSERM, CIC1432, Module épidémiologie Clinique, Dijon, France; Centre Hospitalier Universitaire Dijon-Bourgogne, Centre D'investigation Clinique, Module épidémiologie Clinique/essais Cliniques, Dijon, France
| | - C Lejeune
- Centre de Recherche INSERM LNC-UMR123, Université de Bourgogne Franche-Comté, F-21000, Dijon, France; INSERM, CIC1432, Module épidémiologie Clinique, Dijon, France; Centre Hospitalier Universitaire Dijon-Bourgogne, Centre D'investigation Clinique, Module épidémiologie Clinique/essais Cliniques, Dijon, France
| | - J Albuisson
- Platform of Transfer in Cancer Biology, Department of Biology and Pathology of Tumours, Centre Georges-François Leclerc, Unicancer, F-21000, Dijon, France; Centre de Recherche INSERM LNC-UMR123, Université de Bourgogne Franche-Comté, F-21000, Dijon, France
| | - L Faivre
- Centre de Génétique, FHU TRANSLAD, Institut GIMI, CHU Dijon, F-21000, Dijon, France; CGFL, Unité D'oncogénétique et Institut GIMI, F-21000, Dijon, France.
| |
Collapse
|
3
|
Grienay N, Henaff M, Sagot P, Gompel A, Coutant C, Loustalot C, De Maistre E, Delay E, Costedoat-Chalumeau N, Eric M, Mausservey C, Vinit J. Gigantomastie : un lien étroit avec l’auto-immunité ? Rev Med Interne 2017. [DOI: 10.1016/j.revmed.2017.10.150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
4
|
Vanlemmens L, Congard A, Duprez C, Baudry AS, Lesur A, Loustalot C, Guillemet C, Leclercq M, Levy C, Carlier D, Lefeuvre-Plesse C, Simon H, Frenel JS, Antoine P, Christophe V. Concerns of young women with breast cancer and theirs partners from chemotherapy to follow-up: a cross-sectional study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw390.50] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
5
|
Molly D, Bertaut A, Blanchet C, Beltjens F, Charon-Barra C, Loustalot C, Desmoulins I, Arnould L. Abstract P1-01-14: Do estrogen receptor negative and progesterone receptor positive breast tumors really exist? Attitude for not making them real. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p1-01-14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Breast tumors with negative estrogen receptor (ER-) and positive progesterone receptor (PR+) are rare (from 0 to 3.4 % according to the studies), and their existence is contested. These markers determine cancer molecular subtypes which play a determinant role for both the management and the prognosis of breast cancers. It is then essential to document the real existence of ER-/PR+ tumors. The present study aimed at determining if ER-/PR+ tumors share more basal or luminal characteristics.
Methods: Between 2000 and 2015, 50 patients with ER-/PR+ breast tumors, representing 0.6 % of all breast cancers diagnosed in our institution, were included in this study. Their clinical (age, node status), morphological (size, histological type, Elston and Ellis (EE) grade, necrosis, inflammation, pushing margins, central scar, mitotic index) and immunohistochemical characteristics (ER, PR, HER2, CK5/6 and EGFR status) were compared with those of 50 luminal and 50 triple negative (TN) tumors randomly selected in our lab database. At the time this abstract is written, the Ki67 index determination is still in progress. Five of these ER-/PR+ tumors were also given a molecular test (Nanostring). Qualitative variables were compared using Chi2 or Fisher test, quantitative variables were compared using Student or Mann & Whitney tests. To take into account for multiple comparisons, p-values less than 0.025 were considered as significant.
Results: The results are summarized in table 1. For almost all the analyzed criteria, ER-/PR+ tumors present statistical difference with luminal ones. On the contrary, they share most of TN tumors characteristics. The 5 molecular analyzes performed on ER-/PR+ samples showed the following phenotypes: 3 basal, 1 HER2 enriched and 1 luminal. For this last one, new immunohistological analyzes reveal in fact an ER+ staining.
Table 1: Study results ER-/PR+ tumorsER+ tumorsTN tumorsp ER-/PR+ vs ER+p ER-/PR+ vs TNSize (mm)23.12525.20.00440.4822Histological type0.00120.2424 ductal9480.4100 lobular219.60 neuro-endocrine40 Differentiation<10-40.4497 well09.80 moderately12.548.818 poorly87.541.582 EE grade<10-40.1016 14.135.34 236.74918 359.215.778 EE differentiation<10-40.3197 105.90 214.341.222 385.752.978 EE nuclear atypia<10-40.2227 102 234.774.522 365.325.576 EE mitosis<10-40.0123 124.580.418 230.613.710 344.95.972 Mitotic index (mitoses/mm2)9.52.210.2<10-40.1252Necrosis465.952<10-40.5484Inflammation0.00030.0011 yes30224 no4474.516 weak2623.560 CK5/6 +78.74.280.4<10-40.8378EGFR +44.74.252.2<10-40.4697HER2 +29.87.800.0051<10-4Results are given in %, excepting mitotic index and size
Conclusion: This study tends to support that ER-/PR+ tumors may not exist and are likely to be TN cancers or less frequently false negative ER+ tumors. In a practical point of view, we think that 1) when a tumor shows ER-/PR+ and TN characteristics, it is probably a false positive PR staining, and the tumor has to be considered as a TN one, 2) when an ER-/PR+ tumor don't fit the triple negative tumors characteristics, ER must be retested in order to exclude a true luminal tumor.
Citation Format: Molly D, Bertaut A, Blanchet C, Beltjens F, Charon-Barra C, Loustalot C, Desmoulins I, Arnould L. Do estrogen receptor negative and progesterone receptor positive breast tumors really exist? Attitude for not making them real. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-01-14.
Collapse
Affiliation(s)
- D Molly
- GF Leclerc Cancer Center, Dijon, France
| | - A Bertaut
- GF Leclerc Cancer Center, Dijon, France
| | | | | | | | | | | | - L Arnould
- GF Leclerc Cancer Center, Dijon, France
| |
Collapse
|
6
|
Vanlemmens L, Ploquin A, Delaloge S, Rouzier R, Lesur A, Frenel JS, Loustalot C, Bachelot T, Provansal M, Ferrero JM, Coussy F, Debled M, Kerbrat P, Vinceneux A, Djelila A, Baron M, Jebert S, Decoupigny E, Tresch E, Bonneterre J. Abstract P1-07-02: 5-year overall survival of early breast cancer during pregnancy: A multicenter French case control study. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p1-07-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Breast cancer (BC) during pregnancy (BCP) is a rare situation that requires collaboration between oncologists, surgeons and obstetricians. The main objectives of this study were to compare the overall survival (OS) and disease free survival (DFS) of a multicenter cohort of pregnant patients (pts) with those of matched control pts.
Methods: Patients from 27 centers and diagnosed between 2000 and 2006 with histological confirmed M0 invasive BC were included in this retrospective study. For the cohort of BCP, pts whose pregnancy was interrupted were not eligible. Controls were matched to BCP pts on 5 criteria: clinical T (of TNM), hormonal receptor (HR) status, HER2 status, administration of neo-adjuvant chemotherapy and pathological nodal status in the absence of neo-adjuvant chemotherapy. Survival times were estimated from the date of diagnosis using Kaplan-Meier method. OS was calculated until death from every cause, DFS was calculated until relapse or death from every cause; patients alive were censored at the date of last news.
Results: 100 BCP pts were identified. Their clinical and pathological characteristics were described on a previous presentation (SABCS 2013 P6-06-07). Matched controls could not be found for 12 BCP pts. 88 BCP pts were matched with 204 controls. The only differences between the 2 populations in terms of characteristics or treatment were more radical mastectomy (p=0.036) and fewer taxane administrations in the BCP group (p=0.06). The median duration of follow-up was 8.2 years for cases and 7.7 years for controls. There were no differences between BCP pts and controls in 5-year OS: 83.4%, IC 95% (73.5-89.8) vs 83.8%, IC 95% (77.9-88.3) nor 7-year OS: 76.5% (65.5-84.4) vs 78.1% (71.5-83.3) (p=0.52). The 5-year DFS was 58.6% IC 95% (47.3-68.3) vs 67.2% IC 95% (60.2-73.2) (p= 0.16). However, 5-year DFS was lower in HR+ BCP pts subgroup than in HR+ control group (56.7% IC 95% (40.7-69.8) vs 70.9% IC 95% (61.4-78.5) (p=0.023).
Conclusion: This multicenter French large study confirmed that there are no differences on OS and DFS between pregnant and no pregnant pts, though this might not be true for HR subgroup.
Citation Format: Vanlemmens L, Ploquin A, Delaloge S, Rouzier R, Lesur A, Frenel J-S, Loustalot C, Bachelot T, Provansal M, Ferrero J-M, Coussy F, Debled M, Kerbrat P, Vinceneux A, Djelila A, Baron M, Jebert S, Decoupigny E, Tresch E, Bonneterre J. 5-year overall survival of early breast cancer during pregnancy: A multicenter French case control study. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-07-02.
Collapse
Affiliation(s)
- L Vanlemmens
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut de Cancérologie de l'Ouest - Centre René Gauducheau, St Herblain, France; Centre Georges Francois Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille, France; Centre Antoine Lacassagne, Nices, France; Hopital Saint Louis, Paris, France; Institut Bergonié, Bordeaux, France; Centre Eugene Marquis, Rennes, France; Hopital Universitaire Bretonneau de Tours, Tours, France; Centre Francois Baclesse, Caen, France; Centre Henri Becquerel, Rouen, France
| | - A Ploquin
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut de Cancérologie de l'Ouest - Centre René Gauducheau, St Herblain, France; Centre Georges Francois Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille, France; Centre Antoine Lacassagne, Nices, France; Hopital Saint Louis, Paris, France; Institut Bergonié, Bordeaux, France; Centre Eugene Marquis, Rennes, France; Hopital Universitaire Bretonneau de Tours, Tours, France; Centre Francois Baclesse, Caen, France; Centre Henri Becquerel, Rouen, France
| | - S Delaloge
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut de Cancérologie de l'Ouest - Centre René Gauducheau, St Herblain, France; Centre Georges Francois Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille, France; Centre Antoine Lacassagne, Nices, France; Hopital Saint Louis, Paris, France; Institut Bergonié, Bordeaux, France; Centre Eugene Marquis, Rennes, France; Hopital Universitaire Bretonneau de Tours, Tours, France; Centre Francois Baclesse, Caen, France; Centre Henri Becquerel, Rouen, France
| | - R Rouzier
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut de Cancérologie de l'Ouest - Centre René Gauducheau, St Herblain, France; Centre Georges Francois Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille, France; Centre Antoine Lacassagne, Nices, France; Hopital Saint Louis, Paris, France; Institut Bergonié, Bordeaux, France; Centre Eugene Marquis, Rennes, France; Hopital Universitaire Bretonneau de Tours, Tours, France; Centre Francois Baclesse, Caen, France; Centre Henri Becquerel, Rouen, France
| | - A Lesur
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut de Cancérologie de l'Ouest - Centre René Gauducheau, St Herblain, France; Centre Georges Francois Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille, France; Centre Antoine Lacassagne, Nices, France; Hopital Saint Louis, Paris, France; Institut Bergonié, Bordeaux, France; Centre Eugene Marquis, Rennes, France; Hopital Universitaire Bretonneau de Tours, Tours, France; Centre Francois Baclesse, Caen, France; Centre Henri Becquerel, Rouen, France
| | - J-S Frenel
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut de Cancérologie de l'Ouest - Centre René Gauducheau, St Herblain, France; Centre Georges Francois Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille, France; Centre Antoine Lacassagne, Nices, France; Hopital Saint Louis, Paris, France; Institut Bergonié, Bordeaux, France; Centre Eugene Marquis, Rennes, France; Hopital Universitaire Bretonneau de Tours, Tours, France; Centre Francois Baclesse, Caen, France; Centre Henri Becquerel, Rouen, France
| | - C Loustalot
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut de Cancérologie de l'Ouest - Centre René Gauducheau, St Herblain, France; Centre Georges Francois Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille, France; Centre Antoine Lacassagne, Nices, France; Hopital Saint Louis, Paris, France; Institut Bergonié, Bordeaux, France; Centre Eugene Marquis, Rennes, France; Hopital Universitaire Bretonneau de Tours, Tours, France; Centre Francois Baclesse, Caen, France; Centre Henri Becquerel, Rouen, France
| | - T Bachelot
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut de Cancérologie de l'Ouest - Centre René Gauducheau, St Herblain, France; Centre Georges Francois Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille, France; Centre Antoine Lacassagne, Nices, France; Hopital Saint Louis, Paris, France; Institut Bergonié, Bordeaux, France; Centre Eugene Marquis, Rennes, France; Hopital Universitaire Bretonneau de Tours, Tours, France; Centre Francois Baclesse, Caen, France; Centre Henri Becquerel, Rouen, France
| | - M Provansal
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut de Cancérologie de l'Ouest - Centre René Gauducheau, St Herblain, France; Centre Georges Francois Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille, France; Centre Antoine Lacassagne, Nices, France; Hopital Saint Louis, Paris, France; Institut Bergonié, Bordeaux, France; Centre Eugene Marquis, Rennes, France; Hopital Universitaire Bretonneau de Tours, Tours, France; Centre Francois Baclesse, Caen, France; Centre Henri Becquerel, Rouen, France
| | - J-M Ferrero
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut de Cancérologie de l'Ouest - Centre René Gauducheau, St Herblain, France; Centre Georges Francois Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille, France; Centre Antoine Lacassagne, Nices, France; Hopital Saint Louis, Paris, France; Institut Bergonié, Bordeaux, France; Centre Eugene Marquis, Rennes, France; Hopital Universitaire Bretonneau de Tours, Tours, France; Centre Francois Baclesse, Caen, France; Centre Henri Becquerel, Rouen, France
| | - F Coussy
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut de Cancérologie de l'Ouest - Centre René Gauducheau, St Herblain, France; Centre Georges Francois Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille, France; Centre Antoine Lacassagne, Nices, France; Hopital Saint Louis, Paris, France; Institut Bergonié, Bordeaux, France; Centre Eugene Marquis, Rennes, France; Hopital Universitaire Bretonneau de Tours, Tours, France; Centre Francois Baclesse, Caen, France; Centre Henri Becquerel, Rouen, France
| | - M Debled
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut de Cancérologie de l'Ouest - Centre René Gauducheau, St Herblain, France; Centre Georges Francois Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille, France; Centre Antoine Lacassagne, Nices, France; Hopital Saint Louis, Paris, France; Institut Bergonié, Bordeaux, France; Centre Eugene Marquis, Rennes, France; Hopital Universitaire Bretonneau de Tours, Tours, France; Centre Francois Baclesse, Caen, France; Centre Henri Becquerel, Rouen, France
| | - P Kerbrat
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut de Cancérologie de l'Ouest - Centre René Gauducheau, St Herblain, France; Centre Georges Francois Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille, France; Centre Antoine Lacassagne, Nices, France; Hopital Saint Louis, Paris, France; Institut Bergonié, Bordeaux, France; Centre Eugene Marquis, Rennes, France; Hopital Universitaire Bretonneau de Tours, Tours, France; Centre Francois Baclesse, Caen, France; Centre Henri Becquerel, Rouen, France
| | - A Vinceneux
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut de Cancérologie de l'Ouest - Centre René Gauducheau, St Herblain, France; Centre Georges Francois Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille, France; Centre Antoine Lacassagne, Nices, France; Hopital Saint Louis, Paris, France; Institut Bergonié, Bordeaux, France; Centre Eugene Marquis, Rennes, France; Hopital Universitaire Bretonneau de Tours, Tours, France; Centre Francois Baclesse, Caen, France; Centre Henri Becquerel, Rouen, France
| | - A Djelila
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut de Cancérologie de l'Ouest - Centre René Gauducheau, St Herblain, France; Centre Georges Francois Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille, France; Centre Antoine Lacassagne, Nices, France; Hopital Saint Louis, Paris, France; Institut Bergonié, Bordeaux, France; Centre Eugene Marquis, Rennes, France; Hopital Universitaire Bretonneau de Tours, Tours, France; Centre Francois Baclesse, Caen, France; Centre Henri Becquerel, Rouen, France
| | - M Baron
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut de Cancérologie de l'Ouest - Centre René Gauducheau, St Herblain, France; Centre Georges Francois Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille, France; Centre Antoine Lacassagne, Nices, France; Hopital Saint Louis, Paris, France; Institut Bergonié, Bordeaux, France; Centre Eugene Marquis, Rennes, France; Hopital Universitaire Bretonneau de Tours, Tours, France; Centre Francois Baclesse, Caen, France; Centre Henri Becquerel, Rouen, France
| | - S Jebert
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut de Cancérologie de l'Ouest - Centre René Gauducheau, St Herblain, France; Centre Georges Francois Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille, France; Centre Antoine Lacassagne, Nices, France; Hopital Saint Louis, Paris, France; Institut Bergonié, Bordeaux, France; Centre Eugene Marquis, Rennes, France; Hopital Universitaire Bretonneau de Tours, Tours, France; Centre Francois Baclesse, Caen, France; Centre Henri Becquerel, Rouen, France
| | - E Decoupigny
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut de Cancérologie de l'Ouest - Centre René Gauducheau, St Herblain, France; Centre Georges Francois Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille, France; Centre Antoine Lacassagne, Nices, France; Hopital Saint Louis, Paris, France; Institut Bergonié, Bordeaux, France; Centre Eugene Marquis, Rennes, France; Hopital Universitaire Bretonneau de Tours, Tours, France; Centre Francois Baclesse, Caen, France; Centre Henri Becquerel, Rouen, France
| | - E Tresch
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut de Cancérologie de l'Ouest - Centre René Gauducheau, St Herblain, France; Centre Georges Francois Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille, France; Centre Antoine Lacassagne, Nices, France; Hopital Saint Louis, Paris, France; Institut Bergonié, Bordeaux, France; Centre Eugene Marquis, Rennes, France; Hopital Universitaire Bretonneau de Tours, Tours, France; Centre Francois Baclesse, Caen, France; Centre Henri Becquerel, Rouen, France
| | - J Bonneterre
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut de Cancérologie de l'Ouest - Centre René Gauducheau, St Herblain, France; Centre Georges Francois Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille, France; Centre Antoine Lacassagne, Nices, France; Hopital Saint Louis, Paris, France; Institut Bergonié, Bordeaux, France; Centre Eugene Marquis, Rennes, France; Hopital Universitaire Bretonneau de Tours, Tours, France; Centre Francois Baclesse, Caen, France; Centre Henri Becquerel, Rouen, France
| |
Collapse
|
7
|
Beltjens F, Bertaut A, Pigeonnat S, Loustalot C, Desmoulins I, Charon-Barra C, Coudert B, Fumoleau P, Arveux P, Arnould L. HER2-positivity rates in breast cancer: no variation over time when clinicopathological features and testing are stable. Eur J Cancer Care (Engl) 2015; 26. [DOI: 10.1111/ecc.12404] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/20/2015] [Indexed: 12/18/2022]
Affiliation(s)
- F. Beltjens
- Department of Pathology; Centre GF Leclerc; Dijon France
| | - A. Bertaut
- Biostatistics and Epidemiology Unit; Centre GF Leclerc; Dijon France
| | - S. Pigeonnat
- Department of Pathology; Centre GF Leclerc; Dijon France
| | - C. Loustalot
- Department of Surgery; Centre GF Leclerc; Dijon France
| | - I. Desmoulins
- Department of Medical Oncology; Centre GF Leclerc; Dijon France
| | | | - B. Coudert
- Department of Medical Oncology; Centre GF Leclerc; Dijon France
| | - P. Fumoleau
- Department of Medical Oncology; Centre GF Leclerc; Dijon France
| | - P. Arveux
- Côte d'Or Breast Cancer Registry; Centre GF Leclerc; Dijon France
| | - L. Arnould
- Department of Pathology; Centre GF Leclerc; Dijon France
| |
Collapse
|
8
|
Vanlemmens L, Duprez C, Lesur A, Kaci FA, Congard A, Antoine P, Loustalot C, Guillemet C, Leclercq M, Levy C, Christophe V. Concerns About Sexuality of Young Women with Breast Cancer and Their Partners. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu352.3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
9
|
Vanlemmens L, Delaloge S, Ploquin A, Bachelot T, Frenel JS, Loustalot C, Kerbrat P, Mignot L, Debled M, Allouache D, Vinceneux-Confavreux A, Provansal M, Dalenc F, Mouret-Reynier MA, Lerebours F, Jacot W, Tartas S, Morvan F, Jebert S, Decoupigny E, Rouzier R. Abstract P6-06-07: 5-year disease free-survival results of aggressively-treated breast cancer during pregnancy: Results from a French multicenter study. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p6-06-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Breast cancer (BC) during pregnancy (BCP) is a rare situation that requires multi-disciplinary management. The objectives of this study were to assess the tumor characteristics, clinical course and outcome of such patients (pts).
Methods: French hospitals were invited to collect retrospective clinical, treatment and follow-up data of BCP managed between 2000 and 2006. Pts with histologically confirmed M0, invasive BC and pregnant at diagnosis were included. Pts whose pregnancy was interrupted were not eligible. Survival times were calculated from the date of diagnosis.
Results: 100 BCP pts were identified. Median age was 32 years (24-42). Median gestational age at diagnosis was 25 weeks (3-38). 84% and 13% had palpable breast axillary mass respectively. Clinical stages were 1T0, 21T1, 39T2, 28T3, 6 T4A-C, 2 T4D, 3 TX, 56 N0, 39 N1, 5 NX. Histological analysis identified 85 ductal carcinomas, 4 lobular, 11 others. The histopathological grades was G1 in 4,3%, G2 in 29%, and G3 in 66,7%. Tumor subtype was luminal A in 3%, luminal B in 37% (24HER2-, 13HER2+), luminal undetermined in 6%, triple-negative in 45,9%, Her2 + in 21,3%, and not classified in 2% (HR -, HER 2 unknown). Median time interval between first observation and biopsy was 31 days (0-337), respectively 40 days (0-337) and 15 days (0-172) when the first observation was made by patients or physicians. Median time interval between pathologic diagnosis and treatment was 18 days (0-295). Treatment was initiated after pregnancy for 42 pts, with median time of 18 days after delivery. 97 pts received chemotherapy with a median number of 6 cycles (4-11), 92 with anthracyclin, 44 with taxanes. 53 chemotherapy were administered in neo adjuvant setting among which 25 during pregnancy), and 44 in adjuvant setting (23 during pregnancy). 98 pts underwent surgery (34 during pregnancy), with 57 conservations and 41 mastectomies, 93 pts received radiotherapy and 43 hormone therapy after pregnancy. 10 pts received Trastuzumab. The mean gestational age at delivery was 35 weeks (22-45). All children were alive, with a median weight of 2735 g at birth (550-3740). The 5-year Overall Survival rate is 83% (95%CI 74-89), while Disease Free Survival is 53% (95%CI 43-63). First recurrence site was metastasis in 28, locoregional in 13, controlateral in 9 and other cancers in 2.
Conclusion: Biopsy and treatment intervals remain long among this population. In this large series BCP, there is an excess of triple-negative breast cancer. The 5-year OS rate is higher than previously reported but with DFS is lower. BCP remains an aggressive entity despite adapted treatment. Multivariate analysis will be presented. A comparison of this BCP population to matched controls is ongoing.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P6-06-07.
Collapse
Affiliation(s)
- L Vanlemmens
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon-Bérard, Lyon, France; Centre René Gauducheau, Saint Herblain Cedex, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène-Marquis, Rennes, France; Institut Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre François Baclesse, Caen, France; CHRU, Tours, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Jean- Perrin, Clermont-Ferrand, France; CRLC Val d'Aurelle, Montpellier, France; Centre René Huguenin, Saint-Cloud, France; CHU, Lyon, France; Centre Hospitalier, Pontoise, France
| | - S Delaloge
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon-Bérard, Lyon, France; Centre René Gauducheau, Saint Herblain Cedex, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène-Marquis, Rennes, France; Institut Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre François Baclesse, Caen, France; CHRU, Tours, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Jean- Perrin, Clermont-Ferrand, France; CRLC Val d'Aurelle, Montpellier, France; Centre René Huguenin, Saint-Cloud, France; CHU, Lyon, France; Centre Hospitalier, Pontoise, France
| | - A Ploquin
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon-Bérard, Lyon, France; Centre René Gauducheau, Saint Herblain Cedex, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène-Marquis, Rennes, France; Institut Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre François Baclesse, Caen, France; CHRU, Tours, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Jean- Perrin, Clermont-Ferrand, France; CRLC Val d'Aurelle, Montpellier, France; Centre René Huguenin, Saint-Cloud, France; CHU, Lyon, France; Centre Hospitalier, Pontoise, France
| | - T Bachelot
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon-Bérard, Lyon, France; Centre René Gauducheau, Saint Herblain Cedex, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène-Marquis, Rennes, France; Institut Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre François Baclesse, Caen, France; CHRU, Tours, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Jean- Perrin, Clermont-Ferrand, France; CRLC Val d'Aurelle, Montpellier, France; Centre René Huguenin, Saint-Cloud, France; CHU, Lyon, France; Centre Hospitalier, Pontoise, France
| | - J-S Frenel
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon-Bérard, Lyon, France; Centre René Gauducheau, Saint Herblain Cedex, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène-Marquis, Rennes, France; Institut Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre François Baclesse, Caen, France; CHRU, Tours, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Jean- Perrin, Clermont-Ferrand, France; CRLC Val d'Aurelle, Montpellier, France; Centre René Huguenin, Saint-Cloud, France; CHU, Lyon, France; Centre Hospitalier, Pontoise, France
| | - C Loustalot
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon-Bérard, Lyon, France; Centre René Gauducheau, Saint Herblain Cedex, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène-Marquis, Rennes, France; Institut Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre François Baclesse, Caen, France; CHRU, Tours, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Jean- Perrin, Clermont-Ferrand, France; CRLC Val d'Aurelle, Montpellier, France; Centre René Huguenin, Saint-Cloud, France; CHU, Lyon, France; Centre Hospitalier, Pontoise, France
| | - P Kerbrat
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon-Bérard, Lyon, France; Centre René Gauducheau, Saint Herblain Cedex, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène-Marquis, Rennes, France; Institut Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre François Baclesse, Caen, France; CHRU, Tours, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Jean- Perrin, Clermont-Ferrand, France; CRLC Val d'Aurelle, Montpellier, France; Centre René Huguenin, Saint-Cloud, France; CHU, Lyon, France; Centre Hospitalier, Pontoise, France
| | - L Mignot
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon-Bérard, Lyon, France; Centre René Gauducheau, Saint Herblain Cedex, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène-Marquis, Rennes, France; Institut Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre François Baclesse, Caen, France; CHRU, Tours, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Jean- Perrin, Clermont-Ferrand, France; CRLC Val d'Aurelle, Montpellier, France; Centre René Huguenin, Saint-Cloud, France; CHU, Lyon, France; Centre Hospitalier, Pontoise, France
| | - M Debled
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon-Bérard, Lyon, France; Centre René Gauducheau, Saint Herblain Cedex, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène-Marquis, Rennes, France; Institut Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre François Baclesse, Caen, France; CHRU, Tours, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Jean- Perrin, Clermont-Ferrand, France; CRLC Val d'Aurelle, Montpellier, France; Centre René Huguenin, Saint-Cloud, France; CHU, Lyon, France; Centre Hospitalier, Pontoise, France
| | - D Allouache
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon-Bérard, Lyon, France; Centre René Gauducheau, Saint Herblain Cedex, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène-Marquis, Rennes, France; Institut Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre François Baclesse, Caen, France; CHRU, Tours, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Jean- Perrin, Clermont-Ferrand, France; CRLC Val d'Aurelle, Montpellier, France; Centre René Huguenin, Saint-Cloud, France; CHU, Lyon, France; Centre Hospitalier, Pontoise, France
| | - A Vinceneux-Confavreux
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon-Bérard, Lyon, France; Centre René Gauducheau, Saint Herblain Cedex, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène-Marquis, Rennes, France; Institut Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre François Baclesse, Caen, France; CHRU, Tours, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Jean- Perrin, Clermont-Ferrand, France; CRLC Val d'Aurelle, Montpellier, France; Centre René Huguenin, Saint-Cloud, France; CHU, Lyon, France; Centre Hospitalier, Pontoise, France
| | - M Provansal
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon-Bérard, Lyon, France; Centre René Gauducheau, Saint Herblain Cedex, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène-Marquis, Rennes, France; Institut Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre François Baclesse, Caen, France; CHRU, Tours, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Jean- Perrin, Clermont-Ferrand, France; CRLC Val d'Aurelle, Montpellier, France; Centre René Huguenin, Saint-Cloud, France; CHU, Lyon, France; Centre Hospitalier, Pontoise, France
| | - F Dalenc
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon-Bérard, Lyon, France; Centre René Gauducheau, Saint Herblain Cedex, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène-Marquis, Rennes, France; Institut Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre François Baclesse, Caen, France; CHRU, Tours, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Jean- Perrin, Clermont-Ferrand, France; CRLC Val d'Aurelle, Montpellier, France; Centre René Huguenin, Saint-Cloud, France; CHU, Lyon, France; Centre Hospitalier, Pontoise, France
| | - M-A Mouret-Reynier
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon-Bérard, Lyon, France; Centre René Gauducheau, Saint Herblain Cedex, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène-Marquis, Rennes, France; Institut Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre François Baclesse, Caen, France; CHRU, Tours, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Jean- Perrin, Clermont-Ferrand, France; CRLC Val d'Aurelle, Montpellier, France; Centre René Huguenin, Saint-Cloud, France; CHU, Lyon, France; Centre Hospitalier, Pontoise, France
| | - F Lerebours
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon-Bérard, Lyon, France; Centre René Gauducheau, Saint Herblain Cedex, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène-Marquis, Rennes, France; Institut Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre François Baclesse, Caen, France; CHRU, Tours, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Jean- Perrin, Clermont-Ferrand, France; CRLC Val d'Aurelle, Montpellier, France; Centre René Huguenin, Saint-Cloud, France; CHU, Lyon, France; Centre Hospitalier, Pontoise, France
| | - W Jacot
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon-Bérard, Lyon, France; Centre René Gauducheau, Saint Herblain Cedex, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène-Marquis, Rennes, France; Institut Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre François Baclesse, Caen, France; CHRU, Tours, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Jean- Perrin, Clermont-Ferrand, France; CRLC Val d'Aurelle, Montpellier, France; Centre René Huguenin, Saint-Cloud, France; CHU, Lyon, France; Centre Hospitalier, Pontoise, France
| | - S Tartas
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon-Bérard, Lyon, France; Centre René Gauducheau, Saint Herblain Cedex, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène-Marquis, Rennes, France; Institut Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre François Baclesse, Caen, France; CHRU, Tours, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Jean- Perrin, Clermont-Ferrand, France; CRLC Val d'Aurelle, Montpellier, France; Centre René Huguenin, Saint-Cloud, France; CHU, Lyon, France; Centre Hospitalier, Pontoise, France
| | - F Morvan
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon-Bérard, Lyon, France; Centre René Gauducheau, Saint Herblain Cedex, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène-Marquis, Rennes, France; Institut Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre François Baclesse, Caen, France; CHRU, Tours, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Jean- Perrin, Clermont-Ferrand, France; CRLC Val d'Aurelle, Montpellier, France; Centre René Huguenin, Saint-Cloud, France; CHU, Lyon, France; Centre Hospitalier, Pontoise, France
| | - S Jebert
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon-Bérard, Lyon, France; Centre René Gauducheau, Saint Herblain Cedex, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène-Marquis, Rennes, France; Institut Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre François Baclesse, Caen, France; CHRU, Tours, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Jean- Perrin, Clermont-Ferrand, France; CRLC Val d'Aurelle, Montpellier, France; Centre René Huguenin, Saint-Cloud, France; CHU, Lyon, France; Centre Hospitalier, Pontoise, France
| | - E Decoupigny
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon-Bérard, Lyon, France; Centre René Gauducheau, Saint Herblain Cedex, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène-Marquis, Rennes, France; Institut Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre François Baclesse, Caen, France; CHRU, Tours, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Jean- Perrin, Clermont-Ferrand, France; CRLC Val d'Aurelle, Montpellier, France; Centre René Huguenin, Saint-Cloud, France; CHU, Lyon, France; Centre Hospitalier, Pontoise, France
| | - R Rouzier
- Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon-Bérard, Lyon, France; Centre René Gauducheau, Saint Herblain Cedex, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène-Marquis, Rennes, France; Institut Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre François Baclesse, Caen, France; CHRU, Tours, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Jean- Perrin, Clermont-Ferrand, France; CRLC Val d'Aurelle, Montpellier, France; Centre René Huguenin, Saint-Cloud, France; CHU, Lyon, France; Centre Hospitalier, Pontoise, France
| |
Collapse
|
10
|
Humbert O, Berriolo-Riedinger A, Riedinger JM, Coudert B, Arnould L, Cochet A, Loustalot C, Fumoleau P, Brunotte F. Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes. Ann Oncol 2012; 23:2572-2577. [PMID: 22499859 DOI: 10.1093/annonc/mds071] [Citation(s) in RCA: 70] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND The aim of this study is to evaluate the impact of the different breast cancer subtypes on the tumor (18)F-FDG uptake at baseline and on its changes after the first course of neoadjuvant chemotherapy (NAC). PATIENTS AND METHODS One hundred and fifteen women with newly diagnosed, large or locally advanced breast cancer undergoing NAC were included. Estrogen receptor (ER), progesterone receptor (PR) and HER2 status were used to define three major tumor subtypes: triple negative (TN) (ER-/PR-/HER2-), luminal (ER+ and/or PR+; HER2-) and HER2 positive (HER2+). Using Fluorine-18 fluorodeoxyglucose positron emission tomography, the tumoral standard uptake value (SUV) maximal index was measured at baseline and just before the second course of NAC. RESULTS TN tumors presented the highest baseline SUV (11.3 ± 8.5; P < 0.0001). The decrease of SUV after the first course of NAC (ΔSUV) was significantly higher in TN and HER2-positive subtypes (-45% ± 25% and -57% ± 30%, respectively) than in luminal one (-19% ± 35%; P < 0.0001). ΔSUV was a predictive factor of the pathological complete response only in HER2-positive tumors (cut-off = -75%; P < 0.03) with an accuracy of 76%. CONCLUSION The baseline (18)F-FDG tumoral uptake but also its early response to NAC is different according to the immunohistological subtypes of breast cancer.
Collapse
Affiliation(s)
- O Humbert
- Departments of Nuclear Medicine, Dijon, France.
| | | | | | - B Coudert
- Depertment of Medical Oncology, Dijon, France
| | | | - A Cochet
- Departments of Nuclear Medicine, Dijon, France; LE2I, UMR CNRS 5158, Université de Bourgogne, Dijon, France
| | | | - P Fumoleau
- Depertment of Medical Oncology, Dijon, France; LE2I, UMR CNRS 5158, Université de Bourgogne, Dijon, France
| | - F Brunotte
- Departments of Nuclear Medicine, Dijon, France; LE2I, UMR CNRS 5158, Université de Bourgogne, Dijon, France
| |
Collapse
|
11
|
Tunon-de-lara C, Giard S, Baron M, Le-Bouedec G, Garbay JR, Blanchot J, Mollard J, Charitansky H, Martin-Françoise S, Michy T, Fondrinier E, Butarelli M, Loustalot C, Raout I, Macgrogan G. P4-18-02: Sentinel Node Biopsy in Extensive Ductal Carcinoma In Situ (DCIS) Diagnosed by Vacuum-Assisted Macrobiopsy (VAMB) and Treated by Mastectomy: Results of the French Prospective Trial CINNAMOME. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p4-18-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Lymph node evaluation in the management of DCIS has been completely abandoned as a result of the documented low incidence of nodal metastases (<2%) and the significant morbidity of lymph node dissection. However, the risk of occult invasive disease exists when the initial diagnosis is performed by vacuum-assisted micro biopsy (VAMB). Invasive disease is usually discovered during the histological analyses following mastectomy. After mastectomy, the only option for patients is complete axillary lymph node dissection (ALND). The aim of this study was to evaluate the number of ALND that can be avoided by using the sentinel lymph node (SLN) procedure to identify patients with invasive disease but no SLN involvement.
Trial design: Patients with extensive microcalcifications on mammography and DCIS diagnosed by VAMB treated by mastectomy were included in the study. The SLN procedure was performed and intraoperative evaluation on frozen sections was carried out. If the SLN was positive an ALND was performed during the same intervention. If the SLN procedure failed or was negative an ALND was not performed. Radiography of the mastectomy specimen was performed to assist the pathologist in confirming the DCIS diagnosis, to evaluate the size and to determine concordance rates between initial VAMB diagnosis and histological analyses. Results: Fourteen French cancer centers took part in this protocol over 2 years (May 2008-December 2010). 228 patients were enrolled, including 197 DCIS on VAMB. The SLN was identified in 193 cases (98%) but one case was not documented at histology leaving 192 valid cases for analysis.
Distribution of SLN results and histological lesions found on mastectomy specimens in the series
ALND was not performed for non-invasive disease and negative SLN (n=114) and invasive or micro-invasive disease and negative SLN (n=51). This meant that ALND was avoided for 67.1% of the patients with invasive disease (51/76, 95%CI[56.5−77.7]), or 26.6% of patients overall (95%CI [20.3−32.8]), whereas these patients would have previously received ALND without the use of the SLN procedure. We observed 39.6% (76/192) of discordance between VAMB results and definitive results from histology analysis after mastectomy across all patients.
Conclusions: SLN is a useful procedure for patients with DCIS diagnosed by VAMB treated by mastectomy and presenting extensive microcalcifications on mammography. For patients for whom microinvasive or invasive carcinoma is later identified on the mastectomy specimen, the use of this procedure makes it possible to spare over a quarter of them from ALND and the associated morbidity. Biological analyses are currently underway to determine predictive factors of invasive disease associated with DCIS.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P4-18-02.
Collapse
Affiliation(s)
- C Tunon-de-lara
- 1Bergonie, Bordeaux, France; Unicancer, Paris, France; CHU, Limoges, France
| | - S Giard
- 1Bergonie, Bordeaux, France; Unicancer, Paris, France; CHU, Limoges, France
| | - M Baron
- 1Bergonie, Bordeaux, France; Unicancer, Paris, France; CHU, Limoges, France
| | - G Le-Bouedec
- 1Bergonie, Bordeaux, France; Unicancer, Paris, France; CHU, Limoges, France
| | - J-R Garbay
- 1Bergonie, Bordeaux, France; Unicancer, Paris, France; CHU, Limoges, France
| | - J Blanchot
- 1Bergonie, Bordeaux, France; Unicancer, Paris, France; CHU, Limoges, France
| | - J Mollard
- 1Bergonie, Bordeaux, France; Unicancer, Paris, France; CHU, Limoges, France
| | - H Charitansky
- 1Bergonie, Bordeaux, France; Unicancer, Paris, France; CHU, Limoges, France
| | | | - T Michy
- 1Bergonie, Bordeaux, France; Unicancer, Paris, France; CHU, Limoges, France
| | - E Fondrinier
- 1Bergonie, Bordeaux, France; Unicancer, Paris, France; CHU, Limoges, France
| | - M Butarelli
- 1Bergonie, Bordeaux, France; Unicancer, Paris, France; CHU, Limoges, France
| | - C Loustalot
- 1Bergonie, Bordeaux, France; Unicancer, Paris, France; CHU, Limoges, France
| | - I Raout
- 1Bergonie, Bordeaux, France; Unicancer, Paris, France; CHU, Limoges, France
| | - G Macgrogan
- 1Bergonie, Bordeaux, France; Unicancer, Paris, France; CHU, Limoges, France
| |
Collapse
|
12
|
Dabakuyo TS, Fraisse J, Causeret S, Gouy S, Padeano MM, Loustalot C, Cuisenier J, Sauzedde JM, Smail M, Combier JP, Chevillote P, Rosburger C, Boulet S, Arveux P, Bonnetain F. A multicenter cohort study to compare quality of life in breast cancer patients according to sentinel lymph node biopsy or axillary lymph node dissection. Ann Oncol 2009; 20:1352-61. [PMID: 19468032 DOI: 10.1093/annonc/mdp016] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND This prospective multicenter study assessed and compared the impact of different surgical procedures on quality of life (QoL) in breast cancer patients. PATIENTS AND METHODS The EORTC QLQ-C30 and the EORTC QLQ-BR-23 questionnaires were used to assess global health status (GHS), arm (BRAS) and breast (BRBS) symptom scales, before surgery, just after surgery and 6 and 12 months later. The Kruskal-Wallis test with the Bonferroni correction was used to compare scores. A mixed model analysis of variance for repeated measurements was then applied to assess the longitudinal effect of surgical modalities on QoL. RESULTS Before surgery, GHS (P = 0.7807) and BRAS (P = 0.7688) QoL scores were similar whatever the surgical procedure: sentinel node biopsy (SLNB), axillary node dissection (ALND) or SLNB + ALND. As compared with other surgical groups, GHS 75.91 [standard deviation (SD) = 17.44, P = 0.041] and BRAS 11.39 (SD = 15.36, P < 0.0001) were better in the SLNB group 12 months after surgery. Whatever the type of surgery, GHS decreased after surgery (P < 0.0001), but increased 6 months later (P = 0.0016). BRAS symptoms increased just after surgery (P = 0.0329) and until 6 months (P < 0.0001) before decreasing (P < 0.0001). CONCLUSIONS SLNB improved GHS and BRAS QoL in breast cancer patients. However, surgeons must be cautious, SLNB with ALND results in a poorer QoL.
Collapse
Affiliation(s)
- T S Dabakuyo
- Biostatistics and Epidemiology Unit, Medical Information Department, Centre Georges François Leclerc, Dijon, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Dabakuyo TS, Fraisse J, Causeret S, Gouy S, Padeano M, Loustalot C, Cuisenier J, Sauzedde J, Boulet S, Bonnetain F. A multicenter cohort to compare quality of life in breast cancer patients according to sentinel lymph node biopsy (SNLB) or full axillary clearance (AC). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.9633] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
14
|
Dabakuyo TSM, Fraisse J, Causeret S, Gouy S, Padeano MM, Loustalot C, Cuisenier J, Sauzedde JM, Boulet S, Bonnetain F. Impact de la technique du ganglion sentinelle (SLNB) appliqué dans le cancer du sein en région Bourgogne. Rev Epidemiol Sante Publique 2008. [DOI: 10.1016/j.respe.2008.03.051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Rouget C, Bardou M, Breuiller-Fouché M, Loustalot C, Qi H, Naline E, Croci T, Cabrol D, Advenier C, Leroy MJ. Beta3-adrenoceptor is the predominant beta-adrenoceptor subtype in human myometrium and its expression is up-regulated in pregnancy. J Clin Endocrinol Metab 2005; 90:1644-50. [PMID: 15585565 DOI: 10.1210/jc.2004-0233] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
Abstract
To assess whether pregnancy might influence the functionality and expression of human myometrial beta(2)- and beta(3)-adrenoceptors (beta(2)- and beta(3)-AR), we performed functional, binding, Western blot, and molecular biology experiments in human nonpregnant and near-term pregnant myometrium. Inhibition of spontaneous contractions induced by a beta(3)-AR agonist, SR 59119A, was significantly greater in pregnant, compared with nonpregnant, myometrial strips (E'(max) = 61 +/- 5% vs. 44 +/- 5% for pregnant and nonpregnant myometrium, respectively), whereas salbutamol, a beta(2)-AR agonist, was significantly less efficient in pregnant, compared with nonpregnant, myometrium (E(max) = 29 +/- 4 vs. 54 +/- 8%). Although two populations of binding sites corresponding to beta(2)- and beta(3)-AR were identified in both nonpregnant and pregnant myometrium, we found a clear predominance of the beta(3)-AR subtype. Moreover, beta(3)-AR binding sites were up-regulated 2-fold in myometrium at the end of pregnancy. Both beta(2)- and beta(3)-AR mRNA were expressed in human nonpregnant and pregnant myometrium. Contrary to beta(2)-AR, the expression of the beta(3)-AR transcripts and immunoreactive proteins was increased in pregnant, compared with nonpregnant, myometrium. Such compelling data suggest a predominant role for beta(3)-AR in the regulation of human myometrium contractility, especially at the end of pregnancy, which might have important consequences for the clinical management of preterm labor.
Collapse
Affiliation(s)
- C Rouget
- Unité Propre de Recherche de l'Enseignement Supérieur EA220-Pharmacology, Unité de Formation et de Recherche Biomédicale des Saints Pères, 45 rue des Saints Pères, F-75006 Paris, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Rouget C, Breuiller-Fouché M, Mercier FJ, Leroy MJ, Loustalot C, Naline E, Frydman R, Croci T, Morcillo EJ, Advenier C, Bardou M. The human near-term myometrial beta 3-adrenoceptor but not the beta 2-adrenoceptor is resistant to desensitisation after sustained agonist stimulation. Br J Pharmacol 2004; 141:831-41. [PMID: 14769781 PMCID: PMC1574252 DOI: 10.1038/sj.bjp.0705616] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
1. In order to compare the beta(2)- and beta(3)-adrenoceptor (beta-AR) desensitisation process in human near-term myometrium, we examined the influence of a pretreatment of myometrial strips with either a beta(2)- or a beta(3)-AR agonist (salbutamol or SR 59119A, respectively, both at 10 microm, for 5 and 15 h) on the relaxation and the cyclic adenosine monophosphate (cAMP) production induced by these agonists. 2. To assess some of the mechanisms potentially implicated in the beta-AR desensitisation process, we studied the influence of such treatment on the number of beta(2)- and beta(3)-AR binding sites, the beta(2)- and beta(3)-AR transcripts expression and the phosphodiesterase 4 (PDE4) activity. 3. Salbutamol, but not SR 59119A, concentration-response curve (CRC) was shifted by a 15 h salbutamol preincubation, with a significant difference in -log EC(20) values (6.31+/-0.13 vs 5.58+/-0.24, for control and 15 h salbutamol pretreatment, respectively, P<0.05). Neither salbutamol nor SR 59119A CRCs were modified after a 15 h preincubation with SR 59119A. 4. A 15 h exposure of myometrial strips to salbutamol significantly reduced the salbutamol-induced (0.60+/-0.26 vs 1.54+/-0.24 pmol mg(-1) protein, P<0.05), but not the SR 59119A-induced, cAMP production. No decrease in cAMP production was observed after a 15 h SR 59119A exposure. 5. A 15 h salbutamol exposure of myometrial strips significantly reduced the beta(2)- but not the beta(3)-AR binding site density, whereas no decrease in the number of beta(2)- and beta(3)-AR binding sites was observed after a 15 h SR 59119A treatment. 6. Neither PDE4 activity nor the beta(2)- and beta(3)-AR mRNA expression levels were affected by salbutamol or SR 59119A treatments. 7. Our results indicate that beta(3)-AR, but not beta(2)-AR, are resistant to the agonist-induced desensitisation. In our model, beta(2)-AR desensitisation is mediated by a decreased number of beta(2)-AR that was not explained by transcriptional regulation of the receptor.
Collapse
Affiliation(s)
- C Rouget
- UPRES EA220-Pharmacology, UFR Biomédicale des Saints Pères, 45 rue des Saints Pères, Paris 75006, France
- INSERM U361, Pavillon Baudelocque, 123 Bd de Port-Royal, Paris 75014, France
- Author for correspondence:
| | - M Breuiller-Fouché
- INSERM U361, Pavillon Baudelocque, 123 Bd de Port-Royal, Paris 75014, France
| | - F J Mercier
- UPRES EA220-Pharmacology, UFR Biomédicale des Saints Pères, 45 rue des Saints Pères, Paris 75006, France
- Department of Anaesthesiology at CHU Antoine Béclère, 157 rue de la Porte de Trivaux, Clamart 92141, France
| | - M J Leroy
- INSERM U361, Pavillon Baudelocque, 123 Bd de Port-Royal, Paris 75014, France
| | - C Loustalot
- Department of Gynaecology CHU du Bocage, 21 Bd de Lattre de Tassigny, BP 1542, Dijon 21000, France
| | - E Naline
- UPRES EA220-Pharmacology, UFR Biomédicale des Saints Pères, 45 rue des Saints Pères, Paris 75006, France
| | - R Frydman
- Department of Gynaecology at CHU Antoine Béclère, 157 rue de la Porte de Trivaux, Clamart 92141, France
| | - T Croci
- Research Centre Sanofi-Midy, Via Piranesi, 38, Milan 20137, Italy
| | - E J Morcillo
- Department of Pharmacology, University of Valencia, Av. Blasco Ibañez 17, Valencia 46010, Spain
| | - C Advenier
- UPRES EA220-Pharmacology, UFR Biomédicale des Saints Pères, 45 rue des Saints Pères, Paris 75006, France
| | - M Bardou
- UPRES EA220-Pharmacology, UFR Biomédicale des Saints Pères, 45 rue des Saints Pères, Paris 75006, France
- Laboratory of Cardiovascular Physiopathology and Pharmacology, Faculty of Medicine, 7 Bd Jeanne d'Arc, BP 87900, Dijon 21079, France
- Author for correspondence:
| |
Collapse
|
17
|
Bardou M, Loustalot C, Simon B, Morcillo E, Croci T, Advenier C. [Inhibition of uterine contractions: new in vitro pharmacological approaches on the pregnant human myometrium]. Therapie 2001; 56:213-22. [PMID: 11475797] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Abstract
The aim of this study was to evaluate the in vitro effects of phosphodiesterase 4 inhibitors (PDE4I) and their combination with salbutamol (beta 2-adrenoceptor agonist) on spontaneous contractions and to investigate by in vitro and biochemical studies and analysis of mRNA expression the presence of beta 3-adrenoceptor in human near-term myometrium. Rolipram, RP 73401 and Ro 20-1724 (PDE4I) inhibited spontaneous myometrial contractions (Emax approximately 100 per cent; pD2 approximately 6.80 for the two first and 6.31 for Ro 20-1724). Rolipram 10(-8) M potentiated the response to salbutamol (Emax = 88 per cent vs. 40 per cent and pD2 = 6.93 and 6.36 with or without rolipram respectively). SR 59119A, a beta 3-adrenoceptor agonist, was more efficient than salbutamol in inhibiting the contractions (Emax 52 per cent and 27 per cent respectively, p < 0.05) but they both induced a significant increase of cAMP production. In both functional and biochemical studies, SR 59119A was only antagonized by the beta 3-adrenoceptor antagonist SR 59230A. The beta 3-AR mRNA was positively expressed in myometrium preparations in a reverse transcription polymerase chain assay. In conclusion, phosphodiesterase 4 inhibitors alone or combined with beta 2-adrenoceptor agonists and beta 3-adrenoceptor agonists might have potential interest as tocolytic agents.
Collapse
Affiliation(s)
- M Bardou
- LPPCE, Faculté de Médecine, 7 bd Jeanne d'Arc, BP 87900, 21079 Dijon, France
| | | | | | | | | | | |
Collapse
|
18
|
Bardou M, Loustalot C, Cortijo J, Simon B, Naline E, Dumas M, Esteve S, Croci T, Chalon P, Frydman R, Sagot P, Manara L, Morcillo EJ, Advenier C. Functional, biochemical and molecular biological evidence for a possible beta(3)-adrenoceptor in human near-term myometrium. Br J Pharmacol 2000; 130:1960-6. [PMID: 10952688 PMCID: PMC1572258 DOI: 10.1038/sj.bjp.0703491] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
The possible existence of a beta(3)-adrenoceptor (beta(3)-AR) in human near-term myometrium was investigated by in vitro functional and biochemical studies and analysis of mRNA expression. SR 59119A and SR 59104A and CGP 12177 (two selective agonists and a partial agonist, respectively, of the beta(3)-AR), salbutamol and terbutaline (beta(2)-AR agonists) each produced a concentration-dependent relaxation of the myometrial spontaneous contractions. There were no differences in pD(2) values for the relaxing potencies of terbutaline, salbutamol, CGP 12177 and SR 59119A. The rank order for their relaxing efficacies was SR 59119A>SR 59104A>terbutaline approximately salbutamol approximately CGP 12177 (E(max)=52+/-7%, 42+/-12% and approximately 30% respectively). Propranolol, a beta(1)- and beta(2)-AR antagonist, and ICI 118551, a beta(2)-AR antagonist (both at 0.1 microM), did not affect the SR 59119A-induced relaxation whereas SR 59230A, a selective beta(3)-AR antagonist (1 microM), significantly reduced the maximal relaxing effect of SR 59119A. SR 59119A and salbutamol induced a significant increase in cyclic AMP levels that was antagonized by SR 59230A but not by propranolol for SR 59119A, and by propranolol but not by SR 59230A for salbutamol. The beta(3)-AR mRNA was positively expressed in myometrium preparations in a reverse transcription polymerase chain assay. The results presented provide the first evidence for the existence of the beta(3)-AR subtype in human near-term myometrium and suggest that the effects of SR 59119A might be mediated through an increase in cyclic AMP level.
Collapse
Affiliation(s)
- M Bardou
- Department of Pharmacology, Faculty of Medicine Paris-Ouest, 15 rue de l'Ecole de Médecine 75006 Paris, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Bardou M, Cortijo J, Loustalot C, Taylor S, Perales-Marín A, Mercier FJ, Dumas M, Deneux-Tharaux C, Frydman R, Morcillo EJ, Advenier C. Pharmacological and biochemical study on the effects of selective phosphodiesterase inhibitors on human term myometrium. Naunyn Schmiedebergs Arch Pharmacol 1999; 360:457-63. [PMID: 10551283 DOI: 10.1007/s002109900092] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
This study was aimed at evaluating the in vitro effects of phosphodiesterase inhibitors and beta2-adrenoceptor agonists on spontaneous contractions of human term myometrium. Rolipram, RP 73401 (3-cyclopentyloxy-N-(3,5(-dichloro-4-pyridil)-4-methoxybenzamide) and Ro 20-1724 (1-4-(3-butoxy-4-methoxybenzyl)-2-imidozolidinone) (phosphodiesterase 4 inhibitors) inhibited spontaneous myometrial contractions (Emax approximately 100%; pD2 of 6.80+/-0.28, 6.84+/-0.32 and 6.31+/-0.03, respectively). Salbutamol and formoterol were less effective (Emax=40+/-6% and 35+/-12%, respectively) than phosphodiesterase 4 inhibitors to reduce myometrial contractility. Inhibitors of phosphodiesterase 3 (milrinone and siguazodan) and 5 (zaprinast) were marginally effective. Rolipram (10-30 nM) and siguazodan (0.1 microM) potentiated the response to salbutamol (Emax=75+/-12%, 88+/-8% and 73+/-12% and pD2=6.51+/-0.20, 6.93+/-0.29 and 6.48+/-0.16, respectively). Sodium nitroprusside (pD2=6.76+/-0.29) and theophylline (pD2=5.15+/-0.22) were effective inhibitors of myometrial contractions. Chromatographic separation of phosphodiesterase isoenzymes demonstrated that phosphodiesterase 4 is predominant but other phosphodiesterase isoenzymes were also identified. In conclusion, phosphodiesterase 4 inhibitors alone or combined with beta2-adrenoceptor agonists have potential interest as tocolytic agents.
Collapse
Affiliation(s)
- M Bardou
- Department of Pharmacology, Faculty of Medicine Paris-Ouest, Paris, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|